Samsara BioCapital’s Abivax ABVX Stock Holding History

Samsara BioCapital’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.34M	Sell	55,095 -1,486	-3%	-$168K	0.6%	19
2026 Q1	$6.3M	Sell	56,581 -18,861	-25%	-$2.23M	0.61%	17
2025 Q4	$10.2M	Hold	75,442	–	–	1.05%	15
2025 Q3	$6.41M	Buy	+75,442	New	+$4.62M	0.84%	17
2025 Q2	–	Sell	-425,000	Closed	-$2.66M	–	30
2025 Q1	$2.66M	Sell	425,000 -425,000	-50%	-$2.88M	0.47%	22
2024 Q4	$6.22M	Hold	850,000	–	–	0.85%	20
2024 Q3	$9.79M	Hold	850,000	–	–	1.88%	15
2024 Q2	$11.2M	Hold	850,000	–	–	2.35%	12
2024 Q1	$12.2M	Hold	850,000	–	–	1.88%	14
2023 Q4	$9.1M	Buy	+850,000	New	+$8.66M	1.41%	15

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Samsara BioCapital's ABVX Position: Q2 2026 in Review

Samsara BioCapital reduced its Abivax (ABVX) stake by 2.6% in Q2 2026, selling an estimated $168K and leaving 55,095 shares worth $7.34M. The position accounts for 0.6% of the portfolio, ranked #19.

Samsara BioCapital first reported a position in ABVX in Q4 2023 and has held it in 10 quarters since. The position peaked at $12.2M in Q1 2024. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Samsara BioCapital held 55,095 shares of Abivax worth $7.34M as of Q2 2026.
Samsara BioCapital sold 1,486 Abivax shares in Q2 2026, an estimated $168K.
Abivax made up 0.6% of Samsara BioCapital's portfolio in Q2 2026, its #19 holding.
Samsara BioCapital first reported a position in Abivax in Q4 2023 and has held it in 10 quarters since.
Samsara BioCapital's Abivax position peaked at $12.2M in Q1 2024.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.